Widely acknowledged, patient non-adherence is America's "other
drug problem." A common patient profile to non-adherence is low
Access to Medicine (ATM). ROI, regulatory, reputation risk and
other pressures may influence how much Pharmco spends on
patient education, a reported paltry 3 percent of marketing and
promotional dollars spent on each patient annually. While ATM
remains a complex equation, more can be done.
In the white paper, "Taking Strategic Leadership: An Approach
for Pharmaceuticals to Invest in Coordinated Patient Adherence
and Access Strategies," MedTera and AccountAbility, outline a 4-
step roadmap to combat these drivers of poor healthcare outcomes,
while driving revenue and corporate social responsibility.